If confusion of amlodipine with amiloride were becoming a problem in a pharmacy,one strategy the Institute for Safe Medication Practices (ISMP) would recommend to help reduce the risk of errors would be to:

This option does not directly address the issue of confusion between amlodipine and amiloride. While therapeutic alternatives can be beneficial in specific cases, they do not solve the problem of misidentification and can lead to further complications in patient care if the alternative is not appropriate for the patient.

Removing amiloride from inventory would not be a practical solution, as it is an essential medication for many patients. This action could lead to a lack of availability for those who need it, potentially compromising their treatment plans and health outcomes.

Eliminating both medications is an extreme measure that would significantly hinder patient care. Both amlodipine and amiloride serve important therapeutic roles, and their removal would adversely affect patients requiring these treatments, causing unnecessary disruption in their healthcare.